Related Experiment Video
Updated: Aug 9, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Superficial granulomatous pyoderma treated with intravenous immunoglobulin
Christopher M Dobson1, Richard A Parslew, Susan Evans
1Department of Dermatology, Royal Liverpool University Hospital, United Kingdom. cdobson8@hotmail.com
Journal of the American Academy of Dermatology
|March 15, 2003
Summary
Superficial granulomatous pyoderma, a rare pyoderma gangrenosum variant, can be aggressive. Intravenous immunoglobulin therapy achieved dramatic and lasting resolution in an unusually severe case.
Area of Science:
- Dermatology
- Histopathology
Background:
- Superficial granulomatous pyoderma (SGP) is a rare pyoderma gangrenosum variant.
- Clinically, SGP presents with superficial ulceration and vegetative margins.
- Histologically, it shows suppurative and granulomatous inflammation, though not pathognomonic.
Observation:
- SGP is generally considered benign and treatment-responsive.
- Published evidence supporting its benign nature and treatment responsiveness is limited.
- This case demonstrated unusually aggressive SGP.
Findings:
- The aggressive SGP case showed dramatic and lasting resolution.
- Treatment with intravenous immunoglobulin (IVIg) was effective.
- IVIg offers a potential therapeutic option for aggressive SGP.
Implications:
- This case challenges the notion of SGP always being benign.
- Intravenous immunoglobulin therapy may be a valuable treatment for aggressive SGP.
- Further research is needed to confirm IVIg efficacy in SGP.
